← Search & browse all drugs

oxyphencyclimine and psycholeptics

A03CA03

Forms & Strengths

Combination product: oxyphencyclimine hydrochloride with psycholeptics (e.g., barbiturates or minor tranquilizers)
Oral tablets

Adult Dosing

10 mg oxyphencyclimine combined with psycholeptic agent taken 2 to 3 times daily before meals
Titrate based on clinical response and anticholinergic side effects

Pediatric Dosing

Safety and efficacy in pediatric patients not established
Not recommended for use in children

Indications

Adjunctive treatment of peptic ulcer disease
Management of irritable bowel syndrome and functional gastrointestinal disorders associated with anxiety

Mechanism of Action

Oxyphencyclimine acts as a competitive muscarinic receptor antagonist, reducing gastric acid secretion and gastrointestinal motility
Psycholeptic component provides central nervous system sedation and reduces anxiety-induced GI hypermotility

Contraindications

Glaucoma (narrow-angle)
Obstructive uropathy (e.g., prostatic hypertrophy)
Obstructive disease of the gastrointestinal tract (achalasia, paralytic ileus, pyloroduodenal stenosis)
Severe hepatic or renal impairment
History of hypersensitivity to anticholinergics or the specific psycholeptic agent

Adverse Reactions

Dry mouth
Blurred vision
Constipation
Urinary retention
Drowsiness and dizziness from the psycholeptic component
Tachycardia and palpitations

Drug Interactions

Enhanced anticholinergic effects when combined with tricyclic antidepressants, antihistamines, or amantadine
Central nervous system depression potentiation when co-administered with alcohol, opioids, or other sedatives
Decreased gastrointestinal absorption of concurrently administered oral medications due to altered motility

Curated Content: Needs Vetting Before Put to Clinical Use